Global Radiopharmaceutical Theranostics Market Share Report 2024, Forecast To 2033
8 Mar, 2024
The radiopharmaceutical theranostics market has seen rapid expansion, rising from $2.51 billion in 2023 to $2.86 billion in 2024, boasting a CAGR of 14.1%. This growth is attributed to advancements in radiopharmaceutical development and clinical research. Predicted growth to $4.9 billion by 2028, with a CAGR of 14.4%, is driven by factors such as biomarker discovery and validation, along with interdisciplinary collaborations. Major trends in the forecast period include the integration of telemedicine, patient-centric care, and the customization of radiopharmaceuticals, as well as developments in nano-theranostics.
Global Radiopharmaceutical Theranostics Market Key Driver
The radiopharmaceutical theranostics market is on the rise owing to the escalating incidence of cancer. With a substantial number of new cancer cases and deaths projected by the American Cancer Society, there's a growing demand for targeted and personalized cancer treatment approaches, as emphasized by the increasing adoption of radiopharmaceutical theranostics.
Get A Free Sample Of The Global Radiopharmaceutical Theranostics Market ReportGlobal Radiopharmaceutical Theranostics Market Segments
The radiopharmaceutical theranostics market covered in this report is segmented –
1) Product Type:Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers
2) Source:Nuclear Reactors, Cyclotrons
3) Radioisotope:Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioscopes
4) Indication:Oncology, Cardiology, Neurology, Other Indications
5) End User:Hospitals, Diagnostic Imaging Centers, Academic And Research Institutes, Other End Users
By Geography: The countries covered in the radiopharmaceutical theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the radiopharmaceutical theranostics market in 2023. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Radiopharmaceutical Theranostics Industry Players
Cardinal Health Inc.; AstraZeneca Plc; GE HealthCare Technologies Inc.; Bayer AG; China Grand Pharmaceutical & Healthcare.; Lantheus Medical Imaging Inc.; Curium Pharma; Advanced Accelerator Applications; Telix Pharmaceuticals Ltd.; Bracco Imaging S.p.A; NTP Radioisotopes SOC Ltd.; Navidea Biopharmaceuticals Inc.; Jubilant DraxImage Inc.; NorthStar Medical Radioisotopes LLC; Blue Earth Diagnostics Ltd.; Precirix NV; SpectronRx; Viewpoint Molecular Targeting Inc.; NuView Life Sciences; Alpha-9 Theranostics Inc.; RadioMedix Inc; RayzeBio Inc; Fusion Pharmaceuticals Inc; Actinium Pharmaceuticals Inc.; Eckert & Ziegler Strahlen- und Medizintechnik AG; Ariceum Therapeutics GmbH; Radiopharm Theranostics Ltd; Ratio Therapeutics Inc; Primo Biotechnology; Bivision Biomedical Technology (Nanjing) Co. Ltd.
Get The Full Global Radiopharmaceutical Theranostics Market Report
Radiopharmaceutical Theranostics Market Overview
Radiopharmaceutical theranostics refers to a combined approach in medicine that combines therapeutics (treatment) and diagnostics (diagnosis) using radiopharmaceuticals. These are used for patient diagnosis, therapy, and personalized management.